Alpha Antitrypsin Deficiency is the most common hereditary disorder in which the body is unable to produce sufficient amount of Alpha-Antitrypsin (AAT) protein. Alpha-Antitrypsin (AAT) protein plays an important role in protecting organs of the body such as liver and lungs from the harmful effects of proteolytic enzymes such as neutrophil elastase. Thus, AATD leads to increased risk of developing a liver disease like Cirrhosis, as well as lung diseases such as Emphysema and Chronic Obstructive Pulmonary Disease (COPD) and Panniculitis.
Visit For Sample Pages:
https://www.delveinsight.com/sample-request/alpha-antitrypsin-deficiency-market
The Alpha Antitrypsin Deficiency market report aslo covers emerging drugs, current treatment practices, Alpha Antitrypsin Deficiency market share of the individual therapies, current and forecasted Alpha Antitrypsin Deficiency Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Alpha Antitrypsin Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Alpha Antitrypsin Deficiency Market Key Facts
-
As per DelveInsight estimates, total prevalent population of AATD in 6 major markets was found to be 1,835,647 in 2017
-
Among the EU5 countries, Germany has the highest prevalent population of AATD with 34,345 cases, followed by the United Kingdom, which has a prevalent population of 27,930 in 2017.
-
Market Size of Alpha antitrypsin deficiency (AATD) in the 6MM was found to be USD 992 million in 2017
-
Men and women are equally affected by Alpha Antitrypsin Deficiency
-
The United States accounts for the largest AATD market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain). Among EU5 countries, Germany had the highest market size, while Spain had the lowest market size of ASD.
Key Benefits of Alpha Antitrypsin Deficiency Market Report
-
Alpha Antitrypsin Deficiency market report provides an in-depth analysis of Alpha Antitrypsin Deficiency Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Alpha Antitrypsin Deficiency market report will help in developing business strategies by understanding the Alpha Antitrypsin Deficiency Market trends & developments, key players and future market competition that will shape and drive the Alpha Antitrypsin Deficiency market in the upcoming years.
-
The Alpha Antitrypsin Deficiency market report covers Alpha Antitrypsin Deficiency current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Alpha Antitrypsin Deficiency market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Alpha Antitrypsin Deficiency Market
The Alpha Antitrypsin Deficiency market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Alpha Antitrypsin Deficiency market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Alpha Antitrypsin Deficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Alpha Antitrypsin Deficiency Epidemiology
The Alpha Antitrypsin Deficiency epidemiology section covers insights about historical and current Alpha Antitrypsin Deficiency patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Alpha Antitrypsin Deficiency Drugs Uptake and Key Market Players
The Alpha Antitrypsin Deficiency Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha Antitrypsin Deficiency market or expected to get launched in the market during the study period. The analysis covers Alpha Antitrypsin Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The key players in Alpha Antitrypsin Deficiency market include
-
Grifols
-
Kamada
-
Shire
-
Behring
-
LFB Biotechnologies
-
Alnylam Pharmaceuticals
-
Dicerna Pharmaceuticals
-
Arrow Head Pharmaceuticals
Table of Content
1. Key Insights
2. Executive Summary
3. Alpha Antitrypsin Deficiency Competitive Intelligence Analysis
4. Alpha Antitrypsin Deficiency Market Overview at a Glance
5. Alpha Antitrypsin Deficiency Disease Background and Overview
6. Alpha Antitrypsin Deficiency Patient Journey
7. Alpha Antitrypsin Deficiency Epidemiology and Patient Population
8. Alpha Antitrypsin Deficiency Treatment Algorithm, Current Treatment, and Medical Practices
9. Alpha Antitrypsin Deficiency Unmet Needs
10. Key Endpoints of Alpha Antitrypsin Deficiency Treatment
11. Alpha Antitrypsin Deficiency Marketed Products
12. Alpha Antitrypsin Deficiency Emerging Therapies
13. Alpha Antitrypsin Deficiency Seven Major Market Analysis
14. Attribute Analysis
15. Alpha Antitrypsin Deficiency Market Outlook (7 major markets)
16. Alpha Antitrypsin Deficiency Access and Reimbursement Overview
17. KOL Views on the Alpha Antitrypsin Deficiency Market.
18. Alpha Antitrypsin Deficiency Market Drivers
19. Alpha Antitrypsin Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related Reports-
Alpha-Antitrypsin Deficiency Epidemiology Forecast to 2030
DelveInsight’s Alpha- Antitrypsin Deficiency – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Alpha- Antitrypsin Deficiency in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Alpha-Antitrypsin Deficiency Pipeline Insights, 2020
Alpha- Antitrypsin Deficiency Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Alpha- Antitrypsin Deficiency market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/